Adjuvant treatment of high-risk renal cell carcinoma: the jury is still out.

Procopio, G; Sepe, P; Verzoni, E; Pignata, S; Bamias, A

Procopio, G; Sepe, P; Verzoni, E; Pignata, S; Bamias, A.

Afiliación

Procopio G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Ringgold Standard Institution, Milano, Italy. Electronic address: giuseppe.procopio@istitutotumori.mi.it.
Sepe P; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Ringgold Standard Institution, Milano, Italy.
Verzoni E; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Ringgold Standard Institution, Milano, Italy.
Pignata S; Department of Urology and Gynecology, NCI, Naples, Italy.
Bamias A; Department of Clinical Therapeutics, National & Kapodistrian University of Athens, Athens, Greece.

Ann Oncol ; 29(10): 2030-2032, 2018 10 01.

Article en En | MEDLINE | ID: mdl-30184148

Asunto(s)

Carcinoma de Células Renales; Neoplasias Renales; Adyuvantes Farmacéuticos; Humanos; Medición de Resultados Informados por el Paciente; Sunitinib

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Etiology_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article Pais de publicación: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google